About Verastem Oncology
Verastem Oncology is a publicly listed company based in Needham (United States) founded in 2010. Small molecule inhibitors targeting cancer stem cell pathways are developed. It operates on a HealthTech model. Verastem Oncology has raised $68.45 million across 11 funding rounds from investors including Bessemer Venture Partners, Hercules Capital and Orbimed. The company has 78 employees. Its chief executive, as recorded, is Brian Stuglik. Verastem Oncology offers products and services including Avutometinib and Defactinib. Its focus areas include Biotechnology and Oncology. Its legal entity is Verastem, Inc.
Company details
Verastem Oncology, operated by Verastem, Inc., is dedicated to the development of innovative treatments for RAS pathway-driven cancers. The company is engaged in creating therapies like Avutometinib, a RAFMEK clamp, and Defactinib, a FAK inhibitor, to address aggressive and recurrent cancers. Solutions are targeted at patients with limited options, particularly those with KRAS, NRAS, and HRAS mutations. Research and clinical trials are prioritized to explore novel combinations and improve outcomes in the oncology sector. The focus is placed on expanding possibilities through customized treatment approaches for difficult-to-treat cancers.
- Headquarters Needham, United States
- Employees 78
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website verastem.com
- Social LinkedIn X
- Legal Name Verastem, Inc.
- Annual Revenue$30.91 M (USD)209.14as on Dec 31, 2025
- Net Profit-$209.47 M (USD)-60.35as on Dec 31, 2025
- EBITDA-$169.4 M (USD)-47.39as on Dec 31, 2025
- Total Equity Funding$68.45M (USD)
in 11 rounds
- Latest Funding Round$75M (USD), Post-IPO
Apr 2025
- InvestorsBessemer Venture Partners
& 19 more
- Employee Count78
Products & Services of Verastem Oncology
Verastem Oncology offers a comprehensive portfolio of products and services, including Avutometinib and Defactinib.
A RAF/MEK clamp blocking cancer signaling pathways effectively.
A FAK inhibitor targeting compensatory cancer growth pathways.
Funding Insights of Verastem Oncology
Verastem Oncology has successfully raised a total of $68.45M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $68.45M
- Total Rounds 11
- Last Round Post-IPO — $75M
- First Round $16M
(Nov 2010)
- Investors Count 20
Latest 10 of 11 funding rounds of Verastem Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $75M | Post-IPO | – | RTW Investments | |
| Feb 2020 | $100M | Post-IPO | – | – | |
| Jan 2020 | $4.83M | Post-IPO | – | – | – |
| Apr 2019 | $75M | Debt – Venture | – | – | |
| Sep 2018 | $200M | Debt – Conventional | – | – | – |
| Mar 2017 | $25M | Debt – Conventional | – | – | |
| Mar 2014 | $3.9M | Post-IPO | – | – | – |
| Jul 2012 | $2M | Post-IPO | – | – | – |
| Nov 2011 | $20.4M | Series C | – | – | |
| Jul 2011 | $32.05M | Series B | – | Advanced Technology Ventures, Astellas Venture Management |
20 investors in total: 20 institutional.
Investors in Verastem Oncology
Verastem Oncology has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Bessemer Venture Partners, Hercules Capital and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Life science & tech focused VC firm investing in early stage companies in the US | cardinalpartners.com | Princeton, United States | ||
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
| astellasventure.com |
Investor details for Verastem Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Verastem Oncology
28 people are tracked at Verastem Oncology (12 in leadership, 11 in board & advisors, 5 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
Brian Stuglik | CEO | Leadership |
Yaofeng C. | Head Of DMPK And Preclinical Safety | Leadership |
Cathy Carew | Chief Organizational Effectiveness Officer | Leadership |
Louis Denis | CMO | Leadership |
Heidi Church | Chief of Staff | Leadership |
Dan Calkins | VP, Finance | Leadership |
Nate Sanburn | Chief Business Officer | Leadership |
Pablo Lee | VP, Head of Clinical Development & Medical Affairs | Leadership |
Cindy Jou Meyers | Senior Director, Regulatory Advertising And Promotion | Leadership |
Patrick Kec | Regional Sales Director | Leadership |
Kerri Helliwell | Senior Director, Supply Chain | Leadership |
Ali Farsidjani | Vice President Of Business Development | Leadership |
John H. Johnson | Director | Board & advisors |
Rob Gagnon | Director | Board & advisors |
Karin Tollefson | Director | Board & advisors |
Michelle Robertson | Director | Board & advisors |
Paul Bunn | Director | Board & advisors |
Eric Rowinsky | Director | Board & advisors |
Mario Sznol | Scientific Advisor | Board & advisors |
Robert Weinberg | Scientific Advisor | Board & advisors |
8 more people are available in the full profile.
Complete people profiles for Verastem Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Verastem Oncology
Verastem Oncology is a publicly listed company on the NASDAQ with ticker symbol VSTM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jan 2012
- Listed onNASDAQ: VSTM
- Listed entityVerastem, Inc.
- Exchange sectorHealth technology
- ISINUS92337C2035
- Share price$7.45 (-9.7% on the day) · 2026-10-13
- Market capitalisation$674.7M
- EPS (diluted, trailing year)$-2.46
- Volume (last session)3,429,243
Financials of Verastem Oncology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $30.9M | -$209.5M | -$169.4M |
| 2024 | $10.0M | -$130.6M | -$114.9M |
| 2023 | -$87.4M | -$92.0M | |
| 2022 | -$73.8M | -$75.4M | |
| 2021 | $606,000 | -$71.2M | -$62.6M |
Detailed financial statements for Verastem Oncology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Verastem Oncology
4 dated milestones of Verastem Oncology across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Verastem Oncology is founded.
- Funding First funding round of $16.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $75.0M.
Web traffic of Verastem Oncology
The website of Verastem Oncology (verastem.com) receives about 7.1K visits a month and ranks #3,436,777 among all websites worldwide, #4,482 in Biotechnology and Pharmaceuticals.
- Monthly visits7.1K
▲ 25.5% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,436,777
among all websites
- Category rank#4,482
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.7
- Average visit8 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Verastem Oncology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vical.com | 100% | View details | |||
 thecancerdiariesmm.blogspot.com | thecancerdiariesmm.blogspot.com | 60% | – | ||
cancernetwork.com | cancernetwork.com | 57% | #396,853 | – |
Top companies in Oncology
3 companies that operate in the same segment as Verastem Oncology (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verastem Oncology
Complete news archive for Verastem Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verastem Oncology
Verastem Oncology was founded in 2010.
Verastem Oncology is headquartered in Needham, United States. It is registered at Needham, Massachusetts, United States.
Brian Stuglik is the CEO of Verastem Oncology, as recorded in our data.
Verastem Oncology is a funded company, having raised a total of $68.45M across 11 funding rounds to date. The company's 1st funding round was a Series B of $32.05M, raised on Nov 2010.
Verastem Oncology has 78 employees.
Annual revenue of Verastem Oncology is $30.91M as on Dec 31, 2025.
Verastem Oncology, operated by Verastem, Inc., is dedicated to the development of innovative treatments for RAS pathway-driven cancers. The company is engaged in creating therapies like Avutometinib, a RAFMEK clamp, and Defactinib, a FAK inhibitor, to address aggressive and recurrent cancers. Solutions are targeted at patients with limited options, particularly those with KRAS, NRAS, and HRAS mutations. Research and clinical trials are prioritized to explore novel combinations and improve outcomes in the oncology sector. The focus is placed on expanding possibilities through customized treatment approaches for difficult-to-treat cancers.
Verastem Oncology offers Avutometinib and Defactinib.
Yes, Verastem Oncology is publicly traded on NASDAQ under the ticker symbol VSTM.
Verastem Oncology has 20 investors. Key investors include Bessemer Venture Partners, Hercules Capital, Orbimed, RTW Investments, and RA Capital.
Verastem Oncology operates through Verastem, Inc..